Projects / Programmes source: ARIS

Cysteine proteinases and their inhibitors in bronchial inflammation and variable airway obstruction in asthma

Research activity

Code Science Field Subfield
3.01.00  Medical sciences  Microbiology and immunology   

Code Science Field
B540  Biomedical sciences  Respiratory system 
B190  Biomedical sciences  Clinical chemistry 
asthma, stefin A, stefin B, cystatin C, cathepsin B, cathepsin H, cathepsin L, cathepsin S, EOS, ECP, MPO, PEF
Evaluation (rules)
source: COBISS
Researchers (9)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  10291  PhD Nina Cimerman  Pharmacy  Researcher  2002 - 2004  117 
2.  15710  PhD Matjaž Fležar  Cardiovascular system  Researcher  2002 - 2004  548 
3.  15781  Izidor Kern  Oncology  Researcher  2002 - 2004  570 
4.  04648  PhD Janko Kos  Biotechnical sciences  Researcher  2002 - 2004  1,151 
5.  10921  PhD Mitja Košnik  Microbiology and immunology  Researcher  2002 - 2004  1,536 
6.  06394  Marta Krašovec  Pharmacy  Researcher  2002 - 2004  83 
7.  06630  PhD Pika Meško Brguljan  Biochemistry and molecular biology  Head  2002 - 2004  344 
8.  09808  PhD Jurij Šorli  Cardiovascular system  Researcher  2002 - 2004  354 
9.  06779  PhD Stanislav Šuškovič  Microbiology and immunology  Researcher  2002 - 2004  411 
Organisations (2)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0259  Krka, tovarna zdravil, d.d., Novo mesto (Slovene)  Novo mesto  5043611  3,759 
2.  1613  University Clinic of Respiratory and Allergic Diseases  Golnik  1190997  7,134 
The objective of this project is to determine whether there is an imbalance between cysteine proteinases cathepsins B, H, L and S, and their low molecular weight inhibitors stefins A and B, and cystatin C in asthmatic sera compared to controls. We are interested whether there is a relationship between the concentrations and molar ratios of these serum proteins to blood number of eosinophils (EOS), serum concentrations of eosinophil cationic protein (ECP) and myeloperoxidase (MPO), and peak expiratory flow rate (PEF) in healthy subjects, steroid-independent and steroid-dependent asthmatic patients. The purpose is also to establish the differences between normal serum and plasma concentrations in order to exclude intracellular contribution from platelets to the measured values in serum and to get more clear information on how the specimen collection affects the preanalytical variation of blood cysteine proteinases and their inhibitors. We will evaluate also the possibility that serum cysteine proteinases and their inhibitors correlate with the response to therapy with methylprednisolone in steroid-independent asthmatic patients, and to cyclosporin A in steroid-dependent asthmatic patients. Besides we will perform immunocyto/immunohistochemical studies in clinical samples of asthmatic patients in order to get some information of their localisation. These results may provide better understanding of the role of cysteine proteinases and their inhibitors in pathophysiological mechanisms of asthma and may be of clinical interest for the evaluation of these serum proteins as additional biochemical parameters for monitoring the disease and the response to therapy.
Views history